Wang B, Deng R, Hennig S, Badovinac Crnjevic T, et al. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer Chemother Pharmacol 2021 Jun 9. pii: 10.1007/s00280-021-04296.
PMID: 34106303